AstraZeneca and IQVIA are teaming up to accelerate development of the UK drugmaker’s Oxford University-partnered COVID-19 vaccine candidate AZD1222, IQVIA announced Tuesday. According to the life sciences data analytics firm, the collaboration will “drive faster delivery of clinical studies” in the US aimed at demonstrating efficacy of the recombinant adenovirus vaccine, formerly known as ChAdOx1 nCoV-19.
The joint initiative, part of the US government’s Operation Warp Speed project, includes an expansive subject study, which is expected to begin enrolling participants this summer and will leverage IQVIA’s virtual trial solutions that would make parts of the study remote.
The UK drugmaker has received US funding of more than $1 billion to secure access to at least 300 million doses of the vaccine. It also recently agreed to supply up to 400 million doses of the vaccine in Europe, with deliveries starting by the end of this year.